Thillaiampalam Sivakumar Selected Research

Babesiosis (Piroplasmosis)

1/2021	Structural and immunological characterization of an epitope within the PAN motif of ectodomain I in Babesia bovis apical membrane antigen 1 for vaccine development.
7/2020	Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.
1/2020	Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
1/2020	Molecular evidence of Babesia caballi and Theileria equi in equines and ticks in Nigeria: prevalence and risk factors analysis.
1/2019	Development of unstable resistance to diminazene aceturate in Babesia bovis.
11/2018	Genetic Analysis of Babesia Isolates from Cattle with Clinical Babesiosis in Sri Lanka.
1/2018	17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.
1/2018	The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites.
10/2017	Chemotherapeutic efficacies of a clofazimine and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on Babesia bovis.
1/2016	Clofazimine Inhibits the Growth of Babesia and Theileria Parasites In Vitro and In Vivo.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thillaiampalam Sivakumar Research Topics

Disease

13	Babesiosis (Piroplasmosis) 01/2021 - 06/2010
5	Infections 01/2022 - 02/2015
4	Parasitemia 07/2020 - 06/2012
3	Malaria 07/2020 - 08/2014
2	Leprosy (Hansen's Disease) 01/2020 - 01/2016
2	Body Weight (Weight, Body) 01/2016 - 06/2012
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2020
1	Anemia 01/2016

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2020 - 06/2010
4	diminazene aceturateIBA 01/2019 - 08/2014
3	Atovaquone (Mepron)FDA Link 01/2022 - 01/2018
3	Clofazimine (Lamprene)FDA Link 01/2022 - 01/2016
3	DNA (Deoxyribonucleic Acid)IBA 11/2018 - 02/2015
2	AntigensIBA 01/2021 - 06/2013
2	VaccinesIBA 01/2021 - 06/2013
2	Mefloquine (Lariam)FDA LinkGeneric 07/2020 - 10/2012
1	EpitopesIBA 01/2021
1	ArtesunateIBA 07/2020
1	tafenoquineIBA 07/2020
1	artemisinin (artemisinine)IBA 07/2020
1	8-aminoquinolineIBA 07/2020
1	Biological ProductsIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	Anti-Infective Agents (Microbicides)IBA 01/2020
1	ImmunosorbentsIBA 03/2018
1	EnzymesIBA 03/2018
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 01/2018
1	imidocarb dipropionateIBA 01/2018
1	AntibodiesIBA 11/2017
1	Mitochondrial DNA (mtDNA)IBA 03/2016
1	pepstatin (pepstatin A)IBA 10/2012
1	Peptide Hydrolases (Proteases)FDA Link 10/2012
1	Thiostrepton (Gargon)IBA 06/2012
1	Rifampin (Rifampicin)FDA LinkGeneric 06/2012
1	Clindamycin (Cleocin)FDA LinkGeneric 06/2012
1	Ciprofloxacin (Cipro)FDA LinkGeneric 06/2012
1	nerolidolIBA 06/2010

Therapy/Procedure

1	Therapeutics 07/2020
1	Combination Drug Therapy (Combination Chemotherapy) 10/2017
1	Drug Therapy (Chemotherapy) 01/2016